Table 1.
Randomized, Placebo-controlled Clinical Trials of Azithromycin
| Country | Participants (n) | Population | PA-Positive | FEV1% Predicted | Pulmonary Exacerbations (Antibiotics) | Weight |
|---|---|---|---|---|---|---|
| United Kingdom (21) | 41 | Children, adolescents | +/− | Improved | Unchanged (i.v.) | Not assessed |
| Australia (22) | 60 | Adults | All | Improved | Reduced (i.v.) | Unchanged |
| United States (8) | 167 | Children, adolescents, adults | All | Improved | Reduced (i.v. and oral ciprofloxacin) | Increased |
| Israel (23) | 18 | Children, adolescents, adults | +/− | Unchanged | Not assessed | Unchanged |
| France (24) | 82 | Children, adolescents | +/− | Unchanged | Reduced (i.v. for PA-positive and oral for all) | Not assessed |
| United States and Canada (10) | 260 | Children, adolescents | None | Unchanged | Reduced (oral only) | Increased |
Definition of abbreviation: PA = Pseudomonas aeruginosa.